Sandoz Group AG (OTCMKTS:SDZNY – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $49.20 and last traded at $49.10, with a volume of 49059 shares changing hands. The stock had previously closed at $48.32.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on SDZNY. BNP Paribas downgraded Sandoz Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 2nd. UBS Group lowered shares of Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Monday, February 3rd.
Read Our Latest Stock Report on Sandoz Group
Sandoz Group Price Performance
About Sandoz Group
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Read More
- Five stocks we like better than Sandoz Group
- Short Selling: How to Short a Stock
- Digital Turbine Roars Back—What’s Driving the Ad Tech Surge?
- How to Use the MarketBeat Excel Dividend Calculator
- 6 Stocks Poised to Benefit From a Trade War in Unexpected Ways
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
